Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

varespladib methyl

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme family of phospholipase A2 produced by the inflammatory cell in… Expand
Review
2013
Review
2013
Introduction: Cardiovascular disease is the most common cause of morbidity and mortality worldwide. Inflammation is responsible… Expand
2011
2011
PurposeSecretory phospholipase A2 group IIA (sPLA2−IIA) concentration and activity are associated with increased risk of… Expand
  • table 1
  • table 2
  • figure 3
  • figure 1
  • figure 2
2011
2011
BackgroundThe action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby… Expand
  • table 1
Highly Cited
2011
Highly Cited
2011
AIMS To investigate the effects of secretory phospholipase A2 (sPLA(2)) inhibition on plasma lipoproteins. Secretory… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
2011
2011
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory… Expand
Highly Cited
2010
Highly Cited
2010
OBJECTIVES The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary… Expand
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2010
Review
2010
Importance of the field: The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving… Expand
Review
2010
Review
2010
Atherosclerosis is not only a lipid-driven disease but it is an intricate process that also involves the simultaneous and… Expand
2009
2009
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the… Expand